Exploratory Study on Companion/Complimentary Diagnosis Platforms for Immune Checkpoint Inhibitor Treatment of Urothelial Cancer Based on Plasma Cell-free DNA

Exploratory Study on Companion/Complimentary Diagnosis Platforms for Immune Checkpoint Inhibitor Treatment of Urothelial Cancer Based on Plasma Cell-free DNA - cfDNA diagnostics for urothelial cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041413

Enrollment

Registered

2020-09-01

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Urothelial cancer patients who have consented to the secondary use of specimens and have both tumor tissue and blood specimens preserved since 2018.

Exclusion criteria

Exclusion criteria: Those who did not give a consent for the secondary use of the sample. Those who opted out the refusal to participate this research.

Design outcomes

Primary

Measure	Time frame
Concordance index of tumor somatic mutation profile based on cfDNA sequence for gene mutation profile, TMB, gene expression profile, immunohistological findings based on tumor tissue.	—

Secondary

Measure	Time frame
Predictive values of tumor somatic mutation profile based on cfDNA sequence for patient prognosis and treatment response.	—

Countries

Japan

Contacts

Public ContactTakashi Kobayashi

Kyoto University Graduate School of Medicine Department of Urology

selecao@kuhp.kyoto-u.ac.jp075-751-3326

Outcome results